Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberta Hoi

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Rheumatology (Oxford, England)|March 11, 2021
Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational studyRangi Kandane-Rathnayake, Worawit Louthrenoo, Vera Golder, et al.
Lupus Science & Medicine|January 20, 2025
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosusRangi Kandane-Rathnayake, Dominique Milea, Worawit Louthrenoo, et al.
Advances in Rheumatology (London, England)|May 9, 2024
Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort studyRicardo Azêdo de Luca Montes, Molla Huq, Timothy Godfrey, et al.
International Journal of Rheumatic Diseases|November 7, 2018
Development of the Asia Pacific Lupus Collaboration cohortRangi Kandane-Rathnayake, Vera Golder, Worawit Louthrenoo, et al.
Lupus Science & Medicine|July 13, 2026
International development of a lupus-specific instrument to assess cognitive symptoms in patients with SLE: Lupus Brain Fog Severity Scale (LBFSS) studyLaurent Arnaud, Matteo Piga, Guillermo J Pons-Estel, et al.
Arthritis Care & Research|July 1, 2021
Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort StudyRangi Kandane-Rathnayake, Worawit Louthrenoo, Shue-Fen Luo, et al.
Lupus Science & Medicine|September 19, 2024
Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosusYanjie Hao, Dylan Hansen, Worawit Louthrenoo, et al.
Annals of the Rheumatic Diseases|December 6, 2025
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatmentNancy Agmon-Levin, Stanislav Ignatenko, Alexander Gordienko, et al.
The Lancet. Rheumatology|January 23, 2024
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort studyKathryn Connelly, Rangi Kandane-Rathnayake, Alberta Hoi, et al.
Annals of the Rheumatic Diseases|February 29, 2024
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort studyYasuhiro Katsumata, Eisuke Inoue, Masayoshi Harigai, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Rheumatology (Oxford, England)|March 11, 2021
Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational studyRangi Kandane-Rathnayake, Worawit Louthrenoo, Vera Golder, et al.
Lupus Science & Medicine|January 20, 2025
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosusRangi Kandane-Rathnayake, Dominique Milea, Worawit Louthrenoo, et al.
Advances in Rheumatology (London, England)|May 9, 2024
Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort studyRicardo Azêdo de Luca Montes, Molla Huq, Timothy Godfrey, et al.
International Journal of Rheumatic Diseases|November 7, 2018
Development of the Asia Pacific Lupus Collaboration cohortRangi Kandane-Rathnayake, Vera Golder, Worawit Louthrenoo, et al.
Lupus Science & Medicine|July 13, 2026
International development of a lupus-specific instrument to assess cognitive symptoms in patients with SLE: Lupus Brain Fog Severity Scale (LBFSS) studyLaurent Arnaud, Matteo Piga, Guillermo J Pons-Estel, et al.
Arthritis Care & Research|July 1, 2021
Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort StudyRangi Kandane-Rathnayake, Worawit Louthrenoo, Shue-Fen Luo, et al.
Lupus Science & Medicine|September 19, 2024
Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosusYanjie Hao, Dylan Hansen, Worawit Louthrenoo, et al.
Annals of the Rheumatic Diseases|December 6, 2025
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatmentNancy Agmon-Levin, Stanislav Ignatenko, Alexander Gordienko, et al.
The Lancet. Rheumatology|January 23, 2024
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort studyKathryn Connelly, Rangi Kandane-Rathnayake, Alberta Hoi, et al.
Annals of the Rheumatic Diseases|February 29, 2024
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort studyYasuhiro Katsumata, Eisuke Inoue, Masayoshi Harigai, et al.
Pageof 9